Compare Regeneron Pharmaceuticals Inc (REGN) vs Remitly Global Inc (RELY) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

RELY trades at $24.83, down 5.12% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.93 significantly exceeding expectations of $0.12. Revenue growth is accelerating, reaching $1.64 billion in 2025, with net income turning positive at $67.93 million. A recent partnership with Etsy expands its payment provider reach, signaling business expansion. Analyst consensus is overwhelmingly bullish with a $31.17 price target, representing 25.5% upside from current levels.

The outlook for RELY is positive given its strong revenue trajectory, improving profitability, and strategic partnerships. Key opportunities include continued market share gains in digital remittances and new monetization avenues. Risks involve competitive pressures in fintech, reliance on economic conditions affecting remittance volumes, and potential volatility despite institutional backing. The stock's current pullback may offer a entry point, but investors should weigh execution risks against growth potential.